Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy and safety of larotrectinib in patients with TRK fusion–pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Tan, Daniel S. W., Lassen, Ulrik N., Leyvraz, Serge, Liu, Yongmei, Patel, Jyoti D., Rosen, Lee, Solomon, Benjamin, Norenberg, Ricarda, Dima, Laura, Brega, Nicoletta, Shen, Lin, Moreno, Victor, Kummar, Shivaani, Lin, Jessica J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830513/
https://www.ncbi.nlm.nih.gov/pubmed/35085007
http://dx.doi.org/10.1200/PO.21.00418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830513/
https://www.ncbi.nlm.nih.gov/pubmed/35085007
http://dx.doi.org/10.1200/PO.21.00418

Ejemplares similares